Kornimate/medical-research-clean huggingface dataset:
mobilization with movement versus soft tissue mobilization in patients with de quervain tenosynovitis

Conditions: De Quervain Syndrome

Summary: this study will investigate the effects of mobilization with movement in addition to soft tissue mobilization on pain and range of motion in patients suffering from de quervain tenosynovitis.

de quervain tenosynovitis also known as stenosing tenosynovitis is a condition which occur when tendons at the base of thumb pinched and become irritated. several treatment options are available like ultrasound, graston therapy, thrust or non-thrust manipulation, mobilization with movement, soft tissue mobilization but this study focus on 2 treatments to improve malalignment of the joint and also reduce pain. first treatment is mobilization with movement in which passive accessory mobilization from therapist while active mobility is performed by patient. second technique is soft tissue mobilization in which passive glides are applied. the purpose of study is to make comparison between mobilization with movement and soft tissue mobilization.

Eligibility criteria:
inclusion criteria: * male and female * 20 to 50 years * subjects with pain in base of thumb (9) * subject with positive fienklstein test exclusion criteria: * history of radiculopathy * history of systemic illness * history of connective tissue disorder * rheumatoid arthritis * history of hand or wrist injury or acute trauma * subject with negative fienklstein test

Keywords: de quervains tenosynovitis pain manual therapy rom
self acupressure on fatigue and sleep quality in epilepsy patients

Conditions: Epilepsy

Summary: the aim of this study is to examine the effect of self-acupressure application on fatigue and sleep quality in epilepsy patients.

acupressure is a therapy method performed with an instrument or hand, fingertip, palm, elbow, knee, thumb relaxation and wrist bands on various points representing the waist organs in our body in order to ensure the continuation and balance of the energy in our body.

Eligibility criteria:
inclusion criteria: * being over 18 years old * volunteering to participate in the research * having the ability to use technological tools * not having a verbal communication disability (hearing and speaking) * not having a diagnosed psychiatric disorder * having a scale score of \>5 on the piper fatigue scale * a score of \>5 on the pittsburgh sleep quality scale

Keywords: self acupressure fatigue sleep quality epilepsy patients
treatment of renal colic in the emergency departement (ed).

Conditions: Renal Colic

Summary: to evaluate the analgesic effect of a standard dose of intravenous magnesium added to intramuscular diclofenac compared to intravenous lidocaine combined to intramuscular diclofenac or intramuscular diclofenac alone in patients presenting to the emergency department with renal colic and whether it can reduce opioid consumption.

magnesium (mgso4) is a n-methyl-d-aspartate (nmda) receptor antagonist and is thought to be involved in the modulation of pain. there has been little direct evidence that mgso4 relieve neuropathic pain and prevents opioid-induced hyperalgesia in humans. intramuscular diclofenac seems to offer the most effective sustained analgesia for renal colic in the ed and has few side effects. lidocain became the agent of choice in visceral and central pain. intravenous lidocain is effective in the management of neuropathic pain such as diabetic neuropathy, post-surgical pain, post herpetic pain, headaches, and neurological malignancies. at low doses, lidocain is known a relatively safe medication. lidocain seems an effective treatment who can be administrated in the renal colic. objective of study : the aim of this study is to evaluate the analgesic effect of a standard dose of intravenous magnesium added to intramuscular diclofenac compared to intravenous lidocain combined to intramuscular diclofenac or intramuscular diclofenac alone in patients presenting to the emergency department with renal colic and whether it can reduce opioid consumption.

Eligibility criteria:
inclusion criteria: * informed consent. * age \> 18years. * confirmed renal colic * with moderate to severe pain (visual analogic scale ≥4). exclusion criteria: * current regular use of analgesics, anticonvulsants, or antidepressants. * analgesia taken within 24 hours . * renal disorder with a low glomerular filtration rate (\< 60ml/min) * neuromuscular disorder. * severe cardiac disease. * pregnant women * contraindication to one of the protocol treatment * inability of the patient to cooperate * allergy to nsaid or lidocaine.

Keywords: acute pain renal colic diclofenac lidocain magnesium sulfate
evaluation of surgery versus primary chemotherapy in resectable signet ring cell gastric adenocarcinoma

Conditions: Signet Ring Cell Gastric Adenocarcinoma

Summary: the adci 002 trial is a large multicenter phase ii-iii prospective randomized controlled trial comparing primary surgery versus primary chemotherapy followed by surgery in patients with a resectable signet ring cell gastric adenocarcinoma


Eligibility criteria:
inclusion criteria: * adenocarcinoma of the stomach or the oesogastric junction of type iii of siewert classification,histologically proven with the presence of signet ring cells (according to who 2000 classification) or diffuse form (according to lauren classification) on pre-therapeutic biopsies * tumoural stage ib, ii or iii (according to uicc-ajcc 2009) * patient judged resectable in a curative intent on inclusion * absence of distant metastasis * absence of peritoneal carcinomatosis during pre-treatment explorative laparoscopy * who performance status 2 or less * age over 18 or under 80 years * weight loss at the time of inclusion \< 15% * neutrophilic polynuclears more than 1500/mm3 * platelets more than 100000/mm3 * creatinine clearance more than 50 ml/min * serum-albumin more than 30 gram/l * bilirubin less than 1,5 normal * prothrombin rate over 80% * absence of prior treatment with chemotherapy or radiotherapy for gastric cancer * absence of kniwn child b or c cirrhosis * left ventricular ejection fraction more than 50% before epirubicin treatment * extension check-up performed within 4 weeks of inclusion * signed written informed consent given by the patient exclusion criteria: * no corresponding to the inclusion criteria * another malignant tumour treated for curative purposes during the past 5 years excepted basocellular skin carcinoma or in situ uterine cervix cancer * allergy to the active substance or one of the excipients in the study drugs * pregnancy or breast-feeding * any other concommitant treatment, immunotherapy or hormonal therapy * history of abdominal or chest radiotherapy * any evolving disorder which is not under control (liver failure, kidney failure, respiratory failure, evolving heart failure or myocardial necrosis during the past 6 months) * patients who cannot be regularly monitored

Keywords: signet ring cell gastric adenocarcinoma peri-operative chemotherapy surgery
natural history of inflammatory muscle diseases

Conditions: Inflammation In Skeletal Muscle

Summary: objective: to collect information and biospecimens (such as blood, muscle, and skin samples) that will be used to research causes and treatments of inflammatory muscle diseases. eligibility: people aged 12 years and older with suspected or confirmed inflammatory muscle disease. healthy volunteers aged 18 years and older are also needed. design: participants will have at least 1 clinic visit. each visit will last 4 to 8 hours. some may return for additional visits. all participants will undergo these procedures (unless they are unable to): * physical exam, including blood and urine tests. * magnetic resonance imaging (mri) scan of the thigh. participants will lie still on a table with padding around 1 thigh. the table will slide into a tube. the scan will last for approximately 40 minutes. some procedures are optional: * muscle biopsy. an area of skin will be numbed. a quarter-inch cut will be made. several pieces of muscle tissue, about the size of grains of rice, will be removed. * skin biopsy. an area of skin will be numbed. a piece of skin about a quarter inch in diameter will be removed. * genetic testing. some of the samples collected may be used for genetic testing.

study description: this is an observational study to characterize the different types of inflammatory myopathies, understand their etiology, pathogenesis, prognosis, and response to different treatments. objectives: primary objective: define the different types of inflammatory muscle diseases, their etiology, pathogenesis, prognostic factors, and response to different treatments. secondary objectives: study different diagnostic modalities that may help to diagnose and monitor the evolution of the disease in patients with myositis. endpoints: primary endpoint: severity of muscle, skin, pulmonary, and joint involvement. study of the immune dysregulation, transcriptomic changes, and genetic modifications in patients with inflammatory muscle diseases. secondary endpoints: utility of standard of care laboratory, radiologic, electrophysiologic, and clinical studies to diagnose and monitor the evolution of the disease in patients with myositis.

Eligibility criteria:
* inclusion criteria: in order to be eligible to participate in this study, an individual must meet all of the following criteria: 1. ability of subject, or legally authorized representative (lar) to understand and the willingness to sign a written informed consent and/or assent document. 2a. patients are adults and minors of age 12 or older, with possible inflammatory myopathy (suspected or confirmed) or 2b. healthy volunteers will be adults aged 18 or older. exclusion criteria: 1. unwilling to participate in research studies or to provide research samples or data.

Keywords: polymyositis dermatomyositis childhood dermatomyositis natural history
sbrt with focal dose escalation on dil in localized prostate cancer

Conditions: Prostate Adenocarcinoma

Summary: stereotactic ablative body radiotherapy (sbrt) is an advanced radiation technique that allows for precise delivery of higher radiation doses in fewer treatment sessions, resulting in a shorter overall treatment duration. the available clinical evidence suggests that sbrt is highly effective in controlling localized prostate cancer (pca) with acceptable side effects. on the other side, dose escalation is a commonly employed strategy in radiotherapy for prostate cancer. recent studies have confirmed a dose-response relationship, demonstrating improved biochemical control with focal dose escalation to the identified dominant intraprostatic lesion (dil) on multiparametric magnetic resonance imaging (mpmri) of the prostate. the hypothesis of this study is that the combination prostate sbrt with focal dose intensification on the dil with preservation of the prostatic urethra, would lead to a higher probability of local control without a significant increase in toxicity compared to standard clinical practice. this is a prospective single-arm phase ii study designed to evaluate the effectiveness, safety and impact on quality of life of focal dose intensification using sbrt technology and extreme hypofractionated radiotherapy.


Eligibility criteria:
inclusion criteria: * histologically confirmed adenocarcinoma of the prostate * primary localized pca, cn0 and cm0, intermediate or high-risk disease according to nccn 2023 * signed written informed consent for this study * t2-t3a clinical stage with visible dil on mpmri * ecog 0-1 * desirable prostate volume (not mandatory) \ 80 cc if urinary function is preserved and dosimetrically feasible * ipss ≤ 18 (international prostate symptom score) exclusion criteria: * unresolved previous prostatitis, symptomatic urethral stenosis * bilateral hip prosthesis * t3b-4 clinical stage or n1 * m1 (presence of distant metastases) * previous surgery at the prostate level (transurethral resection of the prostate) within the last 6 months
clinical tial of er:yag laser snoring treatment

Conditions: Snoring

Summary: two modes of laser (er:yag) treatment for snoring will be compared with sham treatment in a randomized clinical trial.

the aim of this study is to evaluate the clinical outcome of snoring treatment using non-ablative er:yag laser in comparison with sham laser treatment. furthermore, to different modes of er:yag laser will be compared; a long-pulse mode (lp) and proprietary smooth mode (fotona, slovenia).

Eligibility criteria:
inclusion criteria: * signed informed consent form * diagnosis of snoring/apnea including partner information * age greater than 18 years. * apnea-hypopnea index (ahi) less than 30. * no significant nasal stenosis. * bed partner present exclusion criteria: * people who refuse to participate in the study * presence of concomitant disorders and/or diseases * infections in the throat * current use of photosensitive drugs * pregnancy * scarring in the throat * acute pollen allergies * epilepsy * people starting with an extreme diet or weight loss plan * patients who do not want to follow post treatment recommendation concerning food and drinks intake * larynx obstruction (floppy epiglottis) * oropharynx obstruction caused by palatine tonsils (\>50%).

Keywords: laser er:yag nightlase fotona smooth
internet-based treatment for informal caregivers in lithuania lingi

Conditions: Caregiver Distress

Summary: the purpose of this study is to evaluate efficacy of internet intervention for informal caregivers in lithuania in reducing their care-giving burden.

intervention is going to take a form of an internet based cognitive behavioural treatment program (icbt) consisting of eight modules. these are the themes, as listed chronologically: introduction, thoughts, stress and relaxation, problem solving, communication, anxiety, behavioural activation, maintenance. these themes were chosen after considering topics which might be the most useful for someone in a role of an informal caregiver, considering the trans-diagnostic nature of the intervention. effect of the intervention will be compared against a wait-list control group. intervention is in lithuanian.

Eligibility criteria:
inclusion criteria: * must be 18 years old or over * fluent in comprehending, writing and reading lithuanian language * score 24 or more points on the caregiver burden inventory * spent at least last couple of months for providing care * must have internet access and ability to use computer or any other compatible device exclusion criteria: * adverse life experiences as identified by lec * alcohol addiction * having severe physical or mental impairments * suicide risk * severe interpersonal violence * the person in need of care has life expectancy below or approximately around 6 months

Keywords: informal caregivers internet-based cognitive behaviour therapy culturally adapted psychotherapy ehealth caregiver burden
signatures of response and resistance to mosunetuzomab in follicular lymphomas (fl)

Conditions: Follicular Lymphoma

Summary: mosunetuzumab is a t-cell bispecific antibody targeting cd20 and cd3 aiming to redirect t cells to engage and eliminate malignant b cells. bispecific antibodies (bsab) are a promising treatment option which can induce long-term responses in refractory and relapsed b cell lymphoma patients. however, the factors determining the quality and duration of responses are poorly understood.

the objective is to produce a collection of great scientific interest for lymphoma research from celestimo's clinical trial patients' samples to increase knowledge of treatment with mosunetuzumab's for patients with follicular lymphoma (fl). study population involves patients participating to celestimo study in france. 10 sites are expected in this biobanking protocol study biological samples will collected as part of routine care (tissue and blood already sampled in routine and/or celestimo study) at screening, at c4, at c12 or at progressive disease/relapse.

Eligibility criteria:
patients who participate to celestimo study (nct04712097)

Keywords: follicular lymphoma mosunetuzomab resistance cd20-cd3 bispecific antibodies neoplasms lymphatic diseases immunoproliferative disorders
optisense™ performance in detecting atrial episodes

Conditions: Tachyarrhythmias; Atrial Fibrillation

Summary: the sense-af study aims to determine the performance of the optisense lead in sensing fine episodes of atrial tachyarrhythmia/atrial fibrillation (at/af) and rejecting far-field r wave (ffrw). the performance of the lead will be measured as a difference in device-determined time in at/af and surface-ecg determined time in at/af. this measurement will be compared to the control group which will be randomized to receive sjm's tendril™ ra leads.


Eligibility criteria:
inclusion criteria: * patients who meets current icd or crt-d implant indications and receive a st. jude medical icd/crt-d * patients who will receive a new st. jude medical optisense or tendril ra lead as part of their device implant exclusion criteria: * patients with a history of permanent or persistent af * patient's life expectancy is less than 12 months. * patient is pregnant. * patient's age at enrollment is less than 18 years.

Keywords: icd tachyarrhythmias atrial fibrillation patients who meets current icd or crt-d implant indications
determine-preserved - dapagliflozin effect on exercise capacity using a 6-minute walk test in patients with heart failure with preserved ejection fraction

Conditions: Heart Failure With Preserved Ejection Fraction (HFpEF)

Summary: international, multicentre, parallel-group, randomised, double-blind, placebo-controlled, phase iii study evaluating the effect of dapagliflozin on exercise capacity in heart failure patients with preserved ejection fraction (hfpef)


Eligibility criteria:
inclusion criteria: * provision of signed informed consent prior to any study specific procedures * male or female, aged ≥40 years * established documented diagnosis of symptomatic hfpef (nyha functional class ii-iv), which has been present for at least 8 weeks * lvef\>40% and evidence of structural heart disease * elevated nt-probnp levels * patients should receive background standard of care as described below: all patients will be treated according to locally recognised guidelines on standard of care treatment for patients with hfpef. therapy should have been individually optimised and stable for ≥4 weeks (this does not apply to diuretics) and include (unless contraindicated or not tolerated) treatment of co morbidities (including high blood pressure, ischaemic heart disease, atrial fibrillation/flutter). * 6mwd≥100 metres and ≤425 metres at enrolment and randomization exclusion criteria: * presence of any condition that precludes exercise testing * participation in a structured exercise training programme in the 1 month prior to screening or planned to start during the trial * receiving therapy with an sglt2 inhibitor within 4 weeks prior to enrolment or previous intolerance of an sglt2 inhibitor * type 1 diabetes mellitus * egfr \<25 ml/min/1.73 m2 (ckd-epi formula) at enrolment, unstable or rapidly progressing renal disease at time of randomisation * systolic bp \<95 mmhg on 2 consecutive measurements * systolic bp ≥160 mmhg if not on treatment with ≥3 blood pressure lowering medications or ≥180 mmhg irrespective of treatments, on 2 consecutive measurements * current acute decompensated hf or hospitalisation due to decompensated hf \<4 weeks prior to enrolment * mi, unstable angina, coronary revascularization ablation of atrial fibrillation/flutter, valve repair/replacement, implantation of a cardiac resynchronization therapy device within 12 weeks prior to enrolment or planned to undergo any of these operations after randomization. * stroke or transient ischemic attack within 12 weeks prior to enrolment. * primary pulmonary hypertension, chronic pulmonary embolism, severe pulmonary disease including copd. * previous cardiac transplantation or implantation of a ventricular assistance device or similar device, or implantation expected after randomization * hf due to infiltrative cardiomyopathy, active myocarditis, constrictive pericarditis, cardiac tamponade, known genetic hypertrophic cardiomyopathy or obstructive hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy/dysplasia, or uncorrected primary valvular disease
clinical study to test the efficacy and safety of acyc to treat moderate to severe acne

Conditions: Acne

Summary: the primary objective of this study is to compare the efficacy and safety and tolerability of acyc gel and vehicle in the treatment of subjects with acne vulgaris.

the primary objective of this study is to compare the efficacy and safety and tolerability of acyc gel and vehicle in the treatment of subjects with acne vulgaris

Eligibility criteria:
key inclusion criteria: * male or female between the ages of 12 and 40 (inclusive) * written and verbal informed consent must be obtained. * subjects less than 18 years of age must sign an assent for the study and a parent or a legal guardian must sign the informed consent * subject must have moderate to severe acne at the baseline visit * women of childbearing potential must be willing to practice effective contraception for the duration of the study key exclusion criteria: * use of an investigational drug or device within 30 days of enrollment or participation in a research study concurrent with this study * dermatological conditions on the face that could interfere with clinical evaluations

Keywords: acne
fan therapy in copd patients

Conditions: Chronic Obstructive Pulmonary Disease; Breathlessness

Summary: chronic obstructive pulmonary disease (copd) is a common smoking related lung disease. the main symptom in breathlessness. pulmonary rehabilitation (pr) - a supervised group exercise and education class - is an effective intervention in copd to reduce symptoms, improve exercise performance and prevent exacerbations. however some copd patients are unable to to effectively exercise as they are limited by their breathlessness, despite optimal medical management. by reducing their physical activity to avoid the onset of breathlessness, they become deconditioned and then further attempts at exercise make them more breathless, leading to an inactivity cycle. there is a growing evidence base regarding the use of hand hold fan therapy or air therapy to relieve breathlessness at rest. limited studies have looked at the use of fan therapy during exercise, and its role on exercise capacity and recovery time, provisional results which indicate it may also be useful during activity. logically you might expect patients who are less breathless to be able to exercise more, or recover quicker. this study aims to investigate the effects a hand held fan will have on sensation of breathlessness and exercise capacity in patients with copd. this will involve participants undertaking a standardised field walking test ( 6 minute walk test) with and with out the fan and then comparing the distance covered and how they felt during and after exercise. this will better inform how we structure exercise and advice to these patients in the future to empower patients limited by breathlessness.


Eligibility criteria:
inclusion criteria: * chronic obstructive pulmonary disease (forced expiratory volume in 1 second (fev1)/vital capacity ratio \< 70%, with an observed respiratory impairment ( global initiative for chronic obstructive lung disease (gold) stage ii-iv: \< 79% fev1 predicted) * age \> 18 years old * exertional breathlessness with a medical research council (mrc) breathlessness scale greater of equal to 2 exclusion criteria: * recent exacerbation of copd symptoms requiring antibiotics within the preceding 4 weeks * significant cardiovascular or peripheral disease that could influence exercise tolerance and ability to perform exercise test * unable to hold fan to face and mobilise * on long term oxygen therapy or fulfils criteria for ambulatory oxygen * lack of english language competency

Keywords: fan or air therapy